Shield Therapeutics plc (LON:STX – Get Free Report)’s stock price dropped 11.1% during trading on Friday . The stock traded as low as GBX 1.46 ($0.02) and last traded at GBX 1.47 ($0.02). Approximately 6,697,259 shares were traded during mid-day trading, an increase of 20% from the average daily volume of 5,599,792 shares. The stock had previously closed at GBX 1.65 ($0.02).
Shield Therapeutics Stock Down 6.1 %
The firm has a market cap of £12.12 million, a PE ratio of -12.92 and a beta of 0.84. The company has a quick ratio of 2.16, a current ratio of 2.95 and a debt-to-equity ratio of 21.30. The business has a 50-day moving average price of GBX 1.91 and a two-hundred day moving average price of GBX 4.72.
About Shield Therapeutics
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Further Reading
- Five stocks we like better than Shield Therapeutics
- 10 Best Airline Stocks to Buy
- MarketBeat Week in Review – 4/29 – 5/3
- The How and Why of Investing in Biotech Stocks
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- 5 Top Rated Dividend Stocks to Consider
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
